StockData

CareDx vs Veracyte

CDNA and VCYT side by side, both in health services. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How CDNA and VCYT compare

CareDx is the larger company, worth 2.0 times as much as Veracyte ($3.9B against $1.9B).

On earnings, Veracyte is cheaper: it trades at 17.1× trailing earnings, against 30.8× for CareDx.

CareDx grew revenue faster over the last twelve months (38.9% versus 17.3% for Veracyte).

CareDx keeps more of each dollar of sales as profit, with a net margin of 25.9% compared with 20.4% at Veracyte.

Veracyte scores higher on the StockData Score (16 against 12 for CareDx), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricCDNAVCYT
Size and price
Market cap$3.9B$1.9B
Share price$73.72$24.01
Change, 1 year365%−39.8%
Change, 5 years74.0%−42.2%
Beta (5Y)0.841.93
Employees765755
StockData Score
Total score1216 (better)
Valuation score04 (better)
Growth score23 (better)
Performance score4 (better)3
Health score66
Dividend score00
Valuation
P/E30.8×17.1× (better)
P/S7.8×3.4× (better)
P/B8.3×1.4× (better)
EV/EBITDA27.0×12.9× (better)
P/FCF–11.6×
FCF yield–8.6%
Fair value$59.33$36.49
Margin of safety−24.2%34.2% (better)
Growth
Revenue growth (TTM)38.9% (better)17.3%
Revenue growth, 5Y average14.6%34.5% (better)
Net income growth (TTM)82.6%335% (better)
EPS growth (TTM)–324%
Profitability
Gross margin–71.7%
Operating margin23.4% (better)18.8%
Net margin25.9% (better)20.4%
FCF margin–29.5%
Return on equity33.0% (better)8.8%
Return on invested capital69.8% (better)10.0%
Financial health
Debt / equity0.000.00
Current ratio2.319.16 (better)
Altman Z-score14.01 (better)12.54
Piotroski F-score57 (better)
Dividends and buybacks
Shareholder yield0.00%0.00%
Ownership
Held by institutions102%111%
Held by insiders4.8%1.7%
Insider net buying, 12 months−$18.4M (better)−$18.6M
Short interest, % of float14.4%12.1%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.